Lung Diseases Cies Search Engine [selected websites]

Showing posts with label MedImmune. Show all posts
Showing posts with label MedImmune. Show all posts

Jul 28, 2010

Ligand Acquired Milestone and Royalty Interest in AstraZeneca IL-9 Program for Asthma

Ligand PharmaceuticalsMay 21, 2010 - Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that it has purchased from the Genaera Liquidating Trust certain intellectual property and interests in future milestones and royalties for MEDI-528, an IL-9 antibody program under development by AstraZeneca's subsidiary, MedImmune. MEDI-528 is currently in a 320-patient Phase II study for moderate-to-severe asthma.

MedImmune
Ligand paid $2.75 million to the Genaera Liquidating Trust in connection with the purchase. This opportunity arose from initial diligence and work conducted by Biotechnology Value Fund, L.P. (BVF). As part of this transaction and a result of BVF's contributions, Ligand entered into a separate agreement with BVF and certain of its affiliates, whereby BVF and Ligand will share the purchase price and any proceeds from the deal equally. Accordingly, BVF has paid Ligand $1.375 million... Ligand Pharmaceuticals' Press Release -

May 6, 2008

MedImmune : Phase 3 Data Regarding Anti-RSV Antibody To Be Presented at Pediatric Academic Societies (PAS) Annual Meeting

May 4, 2008 - MedImmune announced that researchers are currently presenting results from a MedImmune-sponsored Phase 3 study involving motavizumab, an investigational monoclonal antibody (MAb) that is being evaluated for its potential to prevent serious disease caused by respiratory syncytial virus (RSV) in high-risk pediatric patients. Kate O'Brien, M.D., M.P.H., associate professor at the Center for American Indian Health, Johns Hopkins Bloomberg School of Public Health, is the study's principal investigator. Aruna Chandran, M.D., M.P.H., a trial co-investigator, presents the data today at the Pediatric Academic Societies (PAS) Annual Meeting in Honolulu, HI... MedImmune's Press release -

Apr 28, 2008

MedImmune and Infinity : Preclinical Data Highlighting Potential of Retaspimycin in Treating Non-Small Cell Lung Cancer With Acquired Drug Resistance

April 15, 2008 – Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) and MedImmune announced that preclinical studies evaluating lead drug candidate retaspimycin hydrochloride ("retaspimycin," also known as IPI-504) suggest that retaspimycin represents a novel strategy for the potential treatment of patients with non-small cell lung cancer (NSCLC) who exhibit resistance to Iressa® (gefitinib) or Tarceva® (erlotinib). Data were presented today during the Annual Meeting of the American Association of Cancer Research (AACR) in San Diego, California. Retaspimycin, a selective small molecule inhibitor of heat shock protein 90 (Hsp90), is currently being evaluated in the Phase 2 portion of an ongoing Phase 1/2 clinical trial in patients with advanced non-small cell lung cancer... MedImmune's Press Release - Infinity's Press Release -

Apr 25, 2008

MedImmune : Asthma Program with Start of a Phase 2 Trial in Europe and Australia and First U.S.-Based Clinical Trial for Antibody Targeting IL-13

April 15, 2008 - MedImmune announced that it has advanced its efforts to develop CAT-354, a potential treatment for patients with asthma, with the start of two new trials with a monoclonal antibody (MAb) targeting interleukin-13 (IL-13). One of the studies is a Phase 2 clinical trial in Europe and Australia designed to assess the potential of the anti-IL-13 MAb in patients with uncontrolled asthma despite optimal treatment. The company has also begun dosing patients in the first U.S.-based clinical trial of the antibody, a Phase 1 study to assess pharmacokinetics in healthy adult patients... MedImmune's Press Release -

Mar 25, 2008

Genaera : MedImmune Initiation of Phase 2A Trial of Antibody Targeting Interleukin-9 in Patients with Asthma

March 18th, 2008 -- Genaera Corporation (NASDAQ: GENR) reported that development partner, MedImmune, has initiated its fourth phase 2a clinical trial of MEDI-528, an anti-IL-9 monoclonal antibody (MAb) targeting interleukin-9 (IL-9), in patients with asthma. This clinical trial is designed to assess the potential of MEDI-528 in patients with stable asthma and exercise-induced bronchoconstriction. Genaera and MedImmune entered into a research collaboration and licensing agreement for this program in 2001.MedImmune is currently evaluating MEDI-528 in patients with asthma in a series of phase 2 clinical trials. The goal of the current phase 2a trial is to assess the safety and tolerability of multiple fixed escalating doses of MEDI-528 in adult patients with stable asthma and exerciseinduced bronchoconstriction... Genaera's Press Release - MedImmune's Press Release -

Feb 26, 2008

MedImmune submitted Biologics License Application to FDA for Motavizumab

Feb. 4 , 2008 - MedImmune announced it submitted to the U.S. Food & Drug Administration (FDA) on January 30 a Biologics License Application (BLA) for motavizumab, an investigational monoclonal antibody (MAb) derived from recombinant DNA technology. The motavizumab BLA is supported by clinical trial data from more than 6,000 patients in which safety and efficacy in prevention of serious disease caused by respiratory syncytial virus (RSV) in high-risk pediatric patients were evaluated...MedImmune's Press Release-

Dec 20, 2007

Infinity and Medimmune, Phase 2 Trial of IPI-504 to Assess the Hsp90 Inhibitor’s Potential Anti-Tumor Activity in Patients with Advanced NSCLC

December 19, 2007 – Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) and MedImmune, Inc. announced that the companies have initiated the Phase 2 portion of a Phase 1/2 clinical trial of IPI-504, their lead heat shock protein 90 (Hsp90) inhibitor, in patients with advanced non-small cell lung cancer (NSCLC) ...The goal of this open-label, multi-center clinical trial is to evaluate the anti-tumor activity of IPI-504 in patients with NSCLC... Infinity 's Press Release - MedImmune's Press Release -

Oct 5, 2007

MedImmune , Phase 2 Safety Data for Anti-RSV Antibody and National RSV Surveillance Results

Oct. 4 /PRNewswire/ -- MedImmune, Inc. announced results from two important studies presented at the 2007 Infectious Diseases Society of America (IDSA) 45th Annual Meeting adding to the body of knowledge about respiratory syncytial virus* (RSV). RSV is a viral pathogen that produces annual outbreaks usually between fall and spring. While RSV typically manifests cold-like symptoms in healthy children, it can prove to be a very serious respiratory illness for premature infants and is the leading cause of respiratory infections for newborns each year... MedImmune 's Press Release -